Bharat Biotech’s COVID-19 recombinant nasal vaccine receives approval for restricted use in emergency situation: Mansukh Mandaviya
India’s first intranasal Covid vaccine developed by Bharat Biotech has received approval for restricted use in emergency situation among people aged above 18 years. In a tweet, Health and Family Welfafe Minister Dr. Mansukh Mandaviya has termed this feat as a big boost to India’s fight against Covid-19.
He informed that Bharat Biotech’s recombinant nasal vaccine has been approved by Central Drugs Standard Control Organisation, CDSCO, for primary immunization against COVID-19 in above 18 years age group for restricted use in emergency situation.
Dr. Mandaviya also said, this step will further strengthen government’s collective fight against the pandemic. He said under the leadership of Prime Minister Narendra Modi, India has harnessed its science, research and development, and human resources in the fight against COVID-19. The Minister expressed hope that with the science-driven approach and efforts of all the country will defeat COVID-19.
